Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at Mizuho

Mizuho upgraded shares of Climb Bio (NASDAQ:CLYM) to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Raymond James Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 10th. They issued a “strong-buy” rating and a $25.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Robert W. Baird lifted their target price on shares of Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Friday, March 6th. B. Riley Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Climb Bio in a report on Thursday, March 5th. They set an “outperform” rating and a $12.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Climb Bio has a consensus rating of “Buy” and a consensus price target of $15.89.

Climb Bio Stock Down 2.3%

Shares of CLYM opened at $8.65 on Wednesday. The firm has a market cap of $413.21 million, a PE ratio of -9.72 and a beta of -0.21. The company’s fifty day moving average is $6.75 and its two-hundred day moving average is $4.29. Climb Bio has a fifty-two week low of $1.13 and a fifty-two week high of $9.25.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). As a group, equities research analysts anticipate that Climb Bio will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Climb Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Climb Bio during the 4th quarter valued at $43,000. Blair William & Co. IL acquired a new stake in shares of Climb Bio during the fourth quarter valued at about $44,000. Balyasny Asset Management L.P. acquired a new stake in shares of Climb Bio during the fourth quarter valued at about $57,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Climb Bio during the third quarter valued at about $29,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Climb Bio during the first quarter valued at about $27,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.